Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Pimecrolimus Impresses
VIENNA - The ascomycin derivative pimecrolimus (ASM 981, Elidel) - currently in Phase III trials for the treatment of atopic dermatitis (topical) and psoriasis (oral) - exhibits skin-specific anti-inflammatory activity and has low potential for immunosuppression in both its topical and oral formulations.
Related Videos
Related Content
